SOLID TUMORS HARBORING NTRK FUSION
Clinical trials for SOLID TUMORS HARBORING NTRK FUSION explained in plain language.
Never miss a new study
Get alerted when new SOLID TUMORS HARBORING NTRK FUSION trials appear
Sign up with your email to follow new studies for SOLID TUMORS HARBORING NTRK FUSION, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug shrinks tumors by targeting rare gene flaw in multiple cancers
Disease control CompletedThis study tested the drug larotrectinib in 215 adults with advanced solid tumors that have a specific change in the NTRK gene. The drug blocks the faulty gene's signals to stop cancer growth. The main goal was to see how many patients had their tumors shrink or disappear. Result…
Matched conditions: SOLID TUMORS HARBORING NTRK FUSION
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated May 26, 2026 11:52 UTC
-
New pill targets rare gene in Hard-to-Treat cancers
Disease control CompletedThis study tested a new drug called larotrectinib in 75 adults with advanced solid tumors that have a specific gene change (NTRK fusion). The main goal was to check the drug's safety and find the best dose. Participants had cancers that stopped responding to other treatments or h…
Matched conditions: SOLID TUMORS HARBORING NTRK FUSION
Phase: PHASE1 • Sponsor: Bayer • Aim: Disease control
Last updated May 19, 2026 11:59 UTC